Polaryx Therapeutics, Inc. Common Stock
$2.04
-$0.10 (-4.67%)
$2.02Day Range$2.21
Key Statistics
Market Cap
$101.69M
Shares Outstanding
49.8M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Feb 2, 2026
Round Lot
100
Locale
US
Trading Data
Day Open
$2.09
Day High
$2.21
Day Low
$2.02
Volume
81.5K
VWAP
$2.07
Prev Close
$2.14
Transactions
--
Acc. Volume
--
About Polaryx Therapeutics, Inc. Common Stock
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
PHARMACEUTICAL PREPARATIONSSIC 2834140 EAST RIDGEWOOD AVENUE, PARAMUS, NJ, 07652201-940-7236IPO Feb 2, 2026US / STOCKSActiveWebsite
Identifiers
- CIK
- 0002075320
- Composite FIGI
- BBG01ZPFWW22
- Share Class FIGI
- BBG01ZPFWWC1
- Ticker Root
- PLYX
- SIC Code
- 2834
About Polaryx Therapeutics, Inc. Common Stock (PLYX) Stock
Polaryx Therapeutics, Inc. Common Stock (PLYX) closed the 2026-09-18 session at $2.04, down 4.67% versus the previous close (-0.10). The stock opened at $2.09 and traded between $2.02 and $2.21 during that session. Session trading volume was 82K shares. The volume-weighted average price (VWAP) is $2.07.
Polaryx Therapeutics Inc is a clinical-stage biotechnology company committed to the discovery, development, and commercialization of novel, disease-modifying therapies for rare, pediatric LSDs. Its therapeutic approach focuses on treating the underlying pathophysiology of these diseases and addressing unmet needs. The company's therapeutic pipeline includes PLX-200, PLX-300, and PLX-100, which are orally available small-molecule drug candidates designed to address core pathological mechanisms common to LSDs. The Company has one reportable segment: lysosomal storage disorders. The lysosomal storage disorders segment consists of the Company's costs associated with the preclinical and clinical development of the Company's product candidates.
Polaryx Therapeutics, Inc. Common Stock has a market capitalization of $101.7 million. The company operates in the PHARMACEUTICAL PREPARATIONS industry classification. PLYX is listed on the XNAS exchange. Polaryx Therapeutics, Inc. Common Stock is headquartered in PARAMUS, NJ. The recorded listing date is 2026-02-02.
On this page you can find market PLYX stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the PHARMACEUTICAL PREPARATIONS sector.